Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery.
Training programme in chronic kidney disease spanning from genetic modifiers to drug discovery.
Human R&D, Training
H2020-MSCA-ITN-2019 – Grant Agreement ID 860977
1 January 2020 to 31 December 2023
Chronic kidney disease (CKD) is recognized as an increasing global health problem. It currently affects 10-15% of the worldwide population, is associated with impaired quality of life and reduced life expectancy and represents a significant burden for health care budgets. CKD is characterized by the progressive decline of renal function. Little is known about the mechanisms underlying this progression and the genetic factors that predispose patients to different progression rates. Understanding the physiopathology of CKD is therefore a prerequisite for the development of efficient preventive strategies and diagnostic tools. With this goal in mind, the TrainCKDis project provides an innovative, multidisciplinary, and intersectoral training program, able to prepare top-level young scientists to develop creative solutions for CKD. The proposed research projects addresses key challenges: 1) the identification of genetic and epigenetic modifiers that predispose patients to CKD progression, 2) the identification of pathways and biomarkers for monitoring CKD progression and 3) the identification of novel therapeutic targets to improve the limited treatments for CKD. Within the consortium, GenomeScan hosts an early stage researcher (ESRs) and contributes with the latest Single Cell Sequencing and Next Generation Sequencing (NGS) technologies to the identification of biomarkers of the CKDs.
T.b.a. (ongoing project)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860977.